FindTrial
Sign In

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080222824
Enrollment
Unknown
Registered
2015-04-20
Start date
2015-04-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathic Pain

Interventions

investigational material(s) Generic name etc : Duloxetine (LY248686) INN of investigational material : Duloxetine Therapeutic category code : 119 Other agents affecting central nervous system Dosage a

Sponsors

Shionogi & Co., Ltd.
Lead Sponsor
Eli Lilly and Company
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants present with pain due to bilateral, peripheral neuropathy. And et al.

Exclusion criteria

Exclusion criteria: Participants who have hypersensitivity to multiple medications. Participants who have undergone renal transplant, or are currently undergoing renal dialysis. And et al.

Design outcomes

Primary

MeasureTime frame
Change from Baseline in the Weekly Mean of the 24-Hour Average Pain Score—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026